【本季度信息】
泰格医药披露的数据显示，2026年上半年实现营业收入37.08亿元，同比增长14.1%。公司经调整后净利润为2.78亿元，同比提升31.8%。本报告期毛利率为27.5%，较上年同期下降2.6个百分点。经营活动产生的现金流净额约4.26亿元，同比增长4.2%。
从成本结构看，销售及营销费用达1.10亿元，同比增加1.7%；管理费用为3.53亿元，同比微幅减少0.6%；研发投入为1.39亿元，同比上升9.8%，占整体营收约3.8%。
【业务分项】
分业务看，临床试验技术服务板块上半年收入17.73亿元，同比增长20.7%。临床试验相关及实验室服务板块实现收入19.34亿元，同比增长8.6%。公司指出，这主要受益于行业复苏和在手项目执行进度加快，带动新签订单额和执行单价提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.